Filing Flows › Outlook Therapeutics (OTLK) › Recalls, complaints & regulation
Outlook Therapeutics (OTLK): clinical trials
Outlook Therapeutics (OTLK) beyond its filings: 1 active clinical trial.
Outlook Therapeutics' latest quarter
Outlook Therapeutics, Q3 FY25: revenue $1.5M, net loss $20.2M, operating cash flow −$11.9M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Outlook Therapeutics have?
1 active study on ClinicalTrials.gov, 1 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.